News

MedPage Today on MSN3d
Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
Zepbound outperforms Wegovy in head-to-head weight loss study
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...
Everyday Health on MSN1d
Zepbound Beats Wegovy for Weight Loss in First Head-to-Head Trial
In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...
The New York Times5d
Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug
There were a few anecdotal reports of blood clots in patients whose treatment was interrupted ... Ozempic, Zepbound and Mounjaro to treat obesity, experts say the choices are not so simple.
BioSpace3d
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...